Leerink Partnrs Weighs in on Editas Medicine FY2025 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Editas Medicine in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.06) per share for the year, down from their prior forecast of ($1.05). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for Editas Medicine’s FY2026 earnings at ($0.65) EPS.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.75) EPS for the quarter, hitting analysts’ consensus estimates of ($0.75). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $3.93 million. During the same period last year, the business posted ($0.55) earnings per share. The firm’s quarterly revenue was down 98.9% on a year-over-year basis.

Several other research firms have also issued reports on EDIT. Raymond James lowered Editas Medicine from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. JPMorgan Chase & Co. downgraded Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Stifel Nicolaus downgraded shares of Editas Medicine from a “buy” rating to a “hold” rating and lowered their target price for the stock from $11.00 to $3.00 in a report on Friday, December 13th. Chardan Capital reaffirmed a “neutral” rating on shares of Editas Medicine in a report on Friday, December 13th. Finally, Wells Fargo & Company downgraded Editas Medicine from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $7.00 to $4.00 in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.00.

Editas Medicine Stock Up 5.2 %

Editas Medicine stock opened at $1.41 on Friday. The company has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $3.15. Editas Medicine has a 1-year low of $1.12 and a 1-year high of $11.58.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC grew its stake in shares of Editas Medicine by 10.0% in the second quarter. Millennium Management LLC now owns 2,459,629 shares of the company’s stock worth $11,486,000 after purchasing an additional 223,012 shares during the last quarter. Stifel Financial Corp raised its position in shares of Editas Medicine by 37.9% during the third quarter. Stifel Financial Corp now owns 624,876 shares of the company’s stock worth $2,131,000 after acquiring an additional 171,656 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Editas Medicine by 133.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 529,834 shares of the company’s stock worth $1,807,000 after acquiring an additional 302,652 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in Editas Medicine by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 267,758 shares of the company’s stock valued at $340,000 after acquiring an additional 41,002 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Editas Medicine by 90.4% during the 3rd quarter. Jennison Associates LLC now owns 237,745 shares of the company’s stock worth $811,000 after purchasing an additional 112,857 shares during the last quarter. Institutional investors own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.